miRecule, Inc.
miRecule is a biotechnology company dedicated to developing RNA therapies for cancer and muscular dystrophy. Utilizing their proprietary DREAmiR™ platform, they create highly tailored therapeutics based on genomic patient data, aiming to help patients live symptom-free lives. Their approach involves identifying genetic abnormalities and designing RNA therapeutics that directly target and correct these issues, with a focus on personalized medicine and targeted delivery to diseased tissues.
Industries
Nr. of Employees
small (1-50)
miRecule, Inc.
Patents
Products
Genomics-based RNA discovery platform
An analytics platform that integrates genomic sequencing and clinical outcomes to nominate and prioritize RNA targets for therapeutic development.
Engineered oligonucleotide therapeutics (preclinical candidates)
Chemically modified RNA/oligonucleotide drug candidates designed for enhanced binding, stability, and therapeutic activity against disease-relevant RNA targets (preclinical-stage).
Antibody–oligonucleotide conjugate therapeutic (program licensed to partner)
A muscle-targeted antibody–oligonucleotide conjugate developed to suppress a disease-causing gene in facioscapulohumeral muscular dystrophy; candidate selection and early development were performed prior to exclusive licensing to a pharmaceutical partner for IND-enabling and clinical development.
Genomics-based RNA discovery platform
An analytics platform that integrates genomic sequencing and clinical outcomes to nominate and prioritize RNA targets for therapeutic development.
Engineered oligonucleotide therapeutics (preclinical candidates)
Chemically modified RNA/oligonucleotide drug candidates designed for enhanced binding, stability, and therapeutic activity against disease-relevant RNA targets (preclinical-stage).
Antibody–oligonucleotide conjugate therapeutic (program licensed to partner)
A muscle-targeted antibody–oligonucleotide conjugate developed to suppress a disease-causing gene in facioscapulohumeral muscular dystrophy; candidate selection and early development were performed prior to exclusive licensing to a pharmaceutical partner for IND-enabling and clinical development.
Services
Identification of RNA therapeutic targets by integrating genomic sequencing with clinical outcome data to define patient subsets for targeted therapies.
In vitro and in vivo pharmacology, mechanism-of-action studies, biomarker development, and bioanalytical support to advance programs toward candidate selection.
Development of antibody–oligonucleotide conjugation methods and formulations to enable tissue-selective delivery of RNA therapeutics.
Negotiation and execution of exclusive licenses and collaborations with industry partners to advance development and commercialization.
Identification of RNA therapeutic targets by integrating genomic sequencing with clinical outcome data to define patient subsets for targeted therapies.
In vitro and in vivo pharmacology, mechanism-of-action studies, biomarker development, and bioanalytical support to advance programs toward candidate selection.
Development of antibody–oligonucleotide conjugation methods and formulations to enable tissue-selective delivery of RNA therapeutics.
Negotiation and execution of exclusive licenses and collaborations with industry partners to advance development and commercialization.
Expertise Areas
- RNA therapeutic discovery
- Antibody–oligonucleotide conjugates and targeted delivery
- Genomics-driven patient stratification
- Preclinical pharmacology and biodistribution
Key Technologies
- Patient genomics integration and outcome analytics
- High-throughput cell-based screening
- Chemically modified oligonucleotide design
- Antibody–oligonucleotide conjugation chemistry
News & Updates
miRecule announced the issuance of U.S. Patent No. 12,104,157, which covers engineered oligonucleotides that are modified forms of miR-30 miRNA with superior binding properties, strengthening its intellectual property portfolio.
miRecule won the top spot at the MedCity INVEST Biopharma track competition in Chicago, recognized for its innovative approach to personalized RNA therapeutics.
miRecule and Sanofi partnered to develop a novel RNA therapeutic for FSHD, combining miRecule’s DREAmiR™ platform with Sanofi’s Nanobody® technology.
The collaboration combines miRecule’s RNA discovery and conjugation platforms with Sanofi’s NANOBODY® technology to develop a treatment for FSHD, with potential milestone payments of nearly $400 million.
SOLVE FSHD invested $1 million to support miRecule’s development of a targeted RNA conjugate therapy for FSHD.
miRecule closed a seed round of $5.7 million to fund the development of RNA therapeutics for cancer and muscular dystrophy.
miRecule announced the issuance of U.S. Patent No. 12,104,157, which covers engineered oligonucleotides that are modified forms of miR-30 miRNA with superior binding properties, strengthening its intellectual property portfolio.
miRecule won the top spot at the MedCity INVEST Biopharma track competition in Chicago, recognized for its innovative approach to personalized RNA therapeutics.
miRecule and Sanofi partnered to develop a novel RNA therapeutic for FSHD, combining miRecule’s DREAmiR™ platform with Sanofi’s Nanobody® technology.
The collaboration combines miRecule’s RNA discovery and conjugation platforms with Sanofi’s NANOBODY® technology to develop a treatment for FSHD, with potential milestone payments of nearly $400 million.
SOLVE FSHD invested $1 million to support miRecule’s development of a targeted RNA conjugate therapy for FSHD.
miRecule closed a seed round of $5.7 million to fund the development of RNA therapeutics for cancer and muscular dystrophy.